Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, October 25, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Silencing the FOXP2 Speech Gene Causes Breast Cancer Cells to Metastasize
BIDMC investigators make the surprising discovery that a gene associated with speech and language is linked to advanced breast cancer.
Fast Modeling Of Cancer Mutations
New genome-editing technique enables rapid analysis of genes mutated in tumors.
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
All the Cell’s a Stage
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
ISB Gets $6.5 Million from NCI
Company has received two-year contract to create ‘Cancer Genomics Cloud’ with partners Google and SRA International.
Precise Control Over Genes Results from Game-Changing Research
UCSF invention greatly amplifies power of CRISPR technology.
Unusual Skin Cancer Linked To Chronic Allergy
Scientists have learned that inflammation at the site of an allergic skin rash can promote skin tumor formation if it persists.
New Clues For Early Colorectal Cancer Detection
Study identifies new biomarkers which could help detect colorectal cancer.
New 'Lab-on-a-Chip' Could Revolutionize Early Diagnosis of Cancer
Faster result times, reduced costs, minimal sample demands and better sensitivity of analysis.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv